Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest

StatusCompleted
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Oct 1, 2007
    • Start date: May 2004 to May 2, 2004
    v8
  2. Trial status: Active, Not Recruiting to Completed
    • Secondary endpoints expanded, about 23 words
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  5. Start date: May 2004v4
Show 2 earlier versionsHide 2 earlier versions
  1. Eligibility criteria revised
    • Study title revised
    v3
  2. Study site revisedv2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Recent studies have suggested that arginine-vasopressin could be more effective in the treatment of cardiac arrests. The last published study did not outline obvious improvements in the prognosis of all cardiac arrests but pointed out a possible increased survival rate when arginine-vasopressin is associated with epinephrine. The aim of this study is to compare the efficacy of two successive injections of epinephrine (1 mg) with two successive injections of epinephrine associated with arginine-vasopressin (40 UI) in out-of-hospital cardiac arrests occurring in adult patients. The primary endpoint is the survival rate at hospital admission. The inclusion period lasts 18 months and 2416 patients are planned to be enrolled.
Trial Details
NCT Number NCT00127907
Lead Sponsor Hospices Civils de Lyon
Conditions
(from sponsor)		 Cardiac Arrest
Related terms Heart Arrest
Enrollment 2,416 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov